Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + serplulimab + etoposide + carboplatin
- Development stage
- Unknown
- Lead developer
- Fujian Medical University Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy regimen is being investigated as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). It integrates four distinct therapeutic agents: surufatinib, a small-molecule multi-kinase inhibitor targeting VEGFR1/2/3, FGFR1, and CSF-1R; serplulimab, a humanized monoclonal antibody targeting the PD-1 receptor; and a standard chemotherapy doublet of etoposide and carboplatin. The rationale for this combination is to leverage the anti-angiogenic and tumor microenvironment-modulating effects of surufatinib alongside the immune-reinvigorating properties of serplulimab and the cytotoxic effects of chemotherapy. The regimen is currently being evaluated in a multicenter, open-label Phase I/II trial led by Fujian Cancer Hospital.
- Other names
- surufatinib + serplulimab + chemotherapysurufatinib + serplulimab + etoposide + carboplatin-Fujian Cancer Hospital-small cell lung cancer (extensive stage)
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)TOP2A (DNA topoisomerase II)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on surufatinib + serplulimab + etoposide + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + serplulimab + etoposide + carboplatin.